To see the issue content and the abstract you do not have to login
Please login to download the full articles

Emailadres
Password
Lost password?      Click here!

If you do not have a subscription to Rhinology please consider to take one.
Click here to become a member of the European Rhinologic Society and a subscriber to the journal `RHINOLOGY`, beginning 2017. Subscription including membership fee: Euro 139.-

If you only want to buy this paper please click here
The price of the paper is 25 euro.


Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis

Volume: - Issue:

Firstpage: 0 - Lastpage: 0

J. Palm - I. Steiner - D. Abramov-Sommariva - A. Ammendola - S. Mitzenheim - H. Steindl - M. Wonnemann - C. Bachert

BACKGROUND: The objective of this clinical trial (CRS-02) was to assess the efficacy, safety and tolerability of two dosages of the herbal medicinal product BNO 1016 (Sinupret extract) in patients with chronic rhinosinusitis (CRS).
METHODOLOGY: 929 patients suffering from CRS were enrolled in this randomised placebo-controlled trial with a treatment period of 12 weeks. The primary endpoint was the mean Major Symptom Score (MSS) in week 8 and week 12 compared to placebo. Secondary endpoints included further MSS related parameters and responder rates over time. Pharmacoeconomic endpoints were also analysed. Finally, safety and tolerability were evaluated.
RESULTS: Sinupret extract was not superior over placebo regarding the primary endpoint. However, the results of the secondary endpoints showed a clear trend towards superior efficacy. Therefore, additional post-hoc sensitivity analyses were performed in patients with a baseline MSS over 9 and persistence of disease more than 1 year diagnosed by specialists in otorhinolaryngology. Those patients significantly benefited from Sinupret extract. Therapy was superior for the primary endpoint analysis. Patients were less impaired with respect to work and daily activities. A good safety and tolerability of Sinupret extract was assured in all patients.
CONCLUSIONS: Sinupret extract can safely be administered in patients with CRS. Although the primary endpoint of the study was not significant, a post-hoc subgroup analysis in patients whose disease was diagnosed by a specialist revealed a pronounced treatment effect. Effects in that subgroup were even stronger with longer disease persistence and stronger severity.

J. Palm - I. Steiner - D. Abramov-Sommariva - A. Ammendola - S. Mitzenheim - H. Steindl - M. Wonnemann - C. Bachert - Assessment of efficacy and safety of the herbal medicinal product BNO 1016 in chronic rhinosinusitis
Rhinology -: 0-0, 0000